ASH 2017 – Monday, December 11

Oral Presentations

7AM
Jaroslaw Maciejewski, MD, PhD
Building C, Level 1, C101 Auditorium
Non-random interactions between founder and subclonal mutations shape the clinical and morphological features of MDS

7:15AM
Alok Khorana, MD
Building B, Level 2, B207-B208
RNA sequencing approaches to identify novel biomarkers for venous thromboembolism (VTE) in lung cancer

7:15AM
Jaroslaw Maciejewski, MD, PhD
Building C, Level 2, C208-C210
Somatic PRPF8 mutations in myeloid neoplasia

7:45AM
Jaroslaw Maciejewski, MD, PhD
Building B, Level 5, Murphy BR 1-2
IDH1/2-mutated acute myeloid leukemia has impaired DNA damage response and is sensitive to monotherapy with the PARP inhibitior olaparib

8:15AM
Ronald Sobecks, MD
Building B, Level 3, B312-B314
CK15-02: Comparison of outcomes after myeloablative versus reduced intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

10:30AM
Ronald Sobecks, MD
Building B, Level 3, B312-B314
Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients who underwent reduced intensity conditioning allogeneic HCT: CIBMTR report

3:30PM
Ronald Sobecks, MD
Building C, Level 2, C202-204
Influence of MHC class I chain-related gene A polymorphisms on cytomegalovirus infection rates after allogeneic hematopoietic cell transplantation

3:45PM
Mikkael Sekeres, MD, MS
Building B, Level 5, Murphy BR 1-2
Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: Results of a phase 1 dose escalation and expansion study

4:30PM
Navneet Majhail, MD
Building C, Level 2, C202-C204
Nicord single unit expanded umbilical cord blood transplantation: Final results of a multicenter phase I/II trial

5:30PM
Jaroslaw Maciejewski, MD, PhD
Building B, Level 3, B302-303
Extent and clinical implications of subclonal diversity in paroxysmal nocturnal hemoglobinuria

6:30PM
Yogen Saunthararajah, MD
Building C, Level 1, C101 Auditorium
The mechanisms by which mutant NPM1-uncouples differentiation from proliferation are reversed by several drugs, enabling rational multicomponent noncytotoxic differentiation therapy

6:45PM
Mikkael Sekeres, MD, MS
Building B, Level 5, Murphy BR 1-2
Results of a phase 3 study of elderly patients with newly diagnosed AML treated with sapacitabine and decitabine administered in alternating cycles

7PM
Anjali Advani, MD
Building C, Level 3, Georgia BR 1-3
Role of remission status and prior transplant in optimizing survival outcomes following allogeneic hematopoietic stem transplantation (HSCT) in patients who received inotuzumab ozogamicin (INO) for relapsed / refractory (R/R) acute lymphoblastic leukemia (ALL)

7:30PM
Anjali Advani, MD
Building B, Level 5, Murphy BR 1-2
GMI-1271 improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients: Results of a Phase 1/2 study

Poster Presentations

6 to 8PM
Building A, Level 1, Hall A2

Jaroslaw Maciejewski, MD, PhD
Activation of autophagy in models of SF3B1 mutant MDS

Clonal architecture of TET2 mutations influences the clinical phenotype of patients with myeloid neoplasms

Betty Hamilton, MD
Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation

Deepa Jagadeesh, MD
Prognostic effect of decline in pulmonary function tests after autologous stem cell transplantation

Navneet Majhail, MD
Easy-to-read informed consent form for hematopoietic cell transplantation clinical trials: Results from Blood and Marrow Transplant Clinical Trials Network 1205 study

Ronald Sobecks, MD
Optimal timing of allogeneic stem cell transplantation (allo-SCT) for chronic myeloid leukemia (CML) patients in the tyrosine kinase inhibitor (TKI) era

Keith McCrae, MD
Comparison of FXII activation in human plasma by extracellular vesicles from cancer cells versus nontransformed cells

The impact of detectable ADAMTS13 inhibitor on the clinical presentation and outcome of patients with immune thrombotic thrombocytopenic purpura (iTTP): Analysis using the United States Thrombotic Microangiopathy (USTMA) clinical registry

Factors associated with mortality in immune-mediated thrombotic thrombocytopenic purpura: Results from the USTMA TTP registry

Alok Khorana, MD
Healthcare costs associated with venous thromboembolism in cancer patients treated with anticoagulants

Treatment of cancer-associated venous thrombosis: The Cleveland Clinic experience

VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism

Dana Angelini, MD
Anticoagulant prescription patterns for cancer associated thrombosis: new insights into the use of direct oral anticoagulants

Sudipto Mukherjee, MD
Incidence, treatment patterns, and outcomes of histiocytic disorders in the United States: A forty-year population study

Mikkael Sekeres, MD, MS
Clinical trial inclusion of therapy-related myelodysplastic syndromes (MDS) over the past 20 years

Brian T. Hill, MD, PhD
Applicability of the chronic lymphocytic leukemia (CLL)-IPI on patients treated with front-line ibrutinib in the real world: The case for new prognostic models

The impact of front-line ibrutinib dose reduction and interruption on outcomes in chronic lymphocytic leukemia (CLL) patients

Front-line ibrutinib therapy for chronic lymphocytic leukemia (cll) in the real world: Responses, toxicity, outcomes and subsequent therapies

Disease and patient characteristics, patterns of care, toxicities and outcomes of chronic lymphocytic leukemia (CLL) patients treated with venetoclax: A multicenter study of 204 patients

Real-world evidence for durable treatment responses after toxicity-related discontinuation of idelalisib

Ibrutinib: A risk factor for invasive fungal infections?

Aziz Nazha, MD
Distinct genomic associations to acute myeloid leukemia (AML) progression from myelodysplastic syndromes (MDS)

Model heterogeneity in predicting outcomes in patients with chronic myelomonocytic leukemia (CMML): An overestimation of survival in lower-risk group

Anjali Advani, MD
Clinical and molecular characteristics of therapy-related acute lymphoblastic leukemia

TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal, induces objective responses in patients with advanced, relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

Eric Hsi, MD
Prognostic utility of serum TARC, MDC, IL10 and soluble CD163 levels with positron emission tomography (PET) response-adapted therapy for advanced-stage hodgkin lymphoma (HL): a SWOG S0816 US Intergroup correlative study
please post as soon as possible – week of 11/27